Which SGA has the highest risk of metabolic abnormalities among the Pines?

Olanzapine is recognized for having a significant association with metabolic abnormalities among the second-generation antipsychotics (SGAs), particularly within the subgroup referred to as "Pines." These metabolic side effects include weight gain, dyslipidemia, and an increased risk of type 2 diabetes. In clinical practice, Olanzapine's propensity to cause substantial weight gain is well-documented, with many patients experiencing considerable increases in body mass index (BMI) after initiating treatment.

This metabolic impact occurs due to Olanzapine's antagonistic effects on various neurotransmitter receptors, including histamine and serotonin receptors, which can influence appetite and glucose metabolism. As a result, patients prescribed Olanzapine require regular monitoring of weight and metabolic parameters to manage and mitigate these risks effectively.

In contrast, while other options such as Quetiapine and Clozapine can also lead to metabolic issues, they generally do not carry the same level of risk as Olanzapine. Asenapine, while also belonging to this class, tends to have a lower incidence of metabolic syndrome compared to Olanzapine. Thus, the choice of Olanzapine as having the highest risk of metabolic abnormalities among the Pines is well-subst